About
Monoclonal antibody
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibodyBoston & New England
Team (20)
Clinical Trials (16)
View allTotal Trials
16
As Lead Sponsor
11
As Collaborator
5
Total Enrollment
1,080
By Phase
PHASE2: 6PHASE1: 7PHASE1/PHASE2: 2
By Status
COMPLETED: 8TERMINATED: 4RECRUITING: 1WITHDRAWN: 1UNKNOWN: 1NO_LONGER_AVAILABLE: 1
Clinical Trials Pipeline15 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT05761951Collaborator
Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer
PHASE2Recruiting
60 participants
Started: Aug 29, 2023 · Completed: Jan 31, 2029
NCT05480306Lead Sponsor
Phase 2 Study of DKN-01 in Colorectal Cancer
PHASE2Completed
188 participants
Started: Aug 30, 2022 · Completed: Jul 10, 2025
NCT04363801Lead Sponsor
A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer
PHASE2Terminated
247 participants
Started: Jul 29, 2020 · Completed: Mar 31, 2025
NCT03818997Collaborator
Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer
PHASE2Withdrawn
Started: Dec 31, 2019 · Completed: Apr 30, 2022
NCT04057365Collaborator
Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)
PHASE2Terminated
15 participants
Started: Oct 7, 2019 · Completed: Sep 25, 2022
Locations (1)
Headquarters
Cambridge, MA, United States
Map
Loading map...